RA Capital Management, L.P.

Filings by RA Capital Management, L.P. span 43 companies, the busiest being Vor Biopharma Inc., Artiva Biotherapeutics, Inc. and 89bio, Inc. We count 203 filings; the first trade dates from 4 May 2021 and the latest from 5 October 2026.

Both buying and selling appear: 95 purchases worth €749.6M, against 32 sales worth €144.1M. No amount is published for 8 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 34 share grants and 7 option exercises. So far in 2026, the count stands at 34 purchases and 20 sales.

Half of the purchases are above €1.8M and half below. Scaled by market value, the purchases weigh a median 0.037% of market cap (sample: 19 purchases). On 10 out of 94 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. After 38 purchases with a full 90-day history, the hit rate stands at 47% and the median 90-day move at -2.3%. They describe history only and say nothing certain about the share price ahead.

The newest entry dates from 7 October 2026: a share grant, in Wave Life Sciences Ltd. The latest purchase dates back some time: it was published 79 days ago, on 31 July 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.